Business Wire

EMVCO

19.10.2018 11:02:10 CEST | Business Wire | Press release

Share
EMVCo Publishes Draft EMV® Secure Remote Commerce Specification v0.9 for Public Comment

EMVCo has today published a draft of its EMV® Secure Remote Commerce (SRC) Specification, which is available for download from the EMVCo website and open for a public comment period of 45 days, until Monday 3 December. The global technical body has made the decision to release a draft specification - EMV SRC Specification v0.9 – before finalising the specification to allow as many payment industry participants as possible, including merchants, card issuers and payment networks, the opportunity to review and contribute to v1.0 which will be published in 2019.

The draft EMV SRC Specification provides a foundation that will enable the processing of e-commerce transactions in a consistent, streamlined fashion across a variety of digital channels and devices, including smartphones, tablets, PCs and other connected devices.

When finalised, it is expected that v1.0 of the EMV SRC Specification will:

  • Define interfaces to allow for secure exchanges of payment data across participants in the digital commerce environment.
  • Accommodate options for using dynamic data, such as cryptograms or other transaction unique data, to enhance the security of payment transactions on a merchant’s SRC enabled website, mobile app or other e-commerce platform.
  • Enable compatibility with other technologies such as EMV Payment Tokenisation and EMV 3-D Secure.
  • Facilitate consumer recognition of a common user experience, indicated by an SRC Mark, which conveys to a consumer that a merchant’s e-commerce environment is enabled for EMV SRC.

Stephanie Ericksen, Chair of EMVCo’s Executive Committee, comments: “EMVCo recognises the need to expediently deliver its EMV SRC Specification to help address rising fraud levels in global e-commerce while reducing consumer friction during online checkout.

“Given the high levels of industry interest in the EMV SRC initiative, EMVCo is publishing a draft specification for wider comment before releasing the official 1.0 version. This allows us to expand on the feedback received to date from EMVCo Associates and Subscribers on the specification development, to help ensure that the EMV SRC Specification addresses the needs of stakeholders across the industry.”

Merchants, card issuers, payment networks, consumers and other stakeholders will benefit from participation in the SRC ecosystem. Consumers will be provided with a choice of payment options and a more consistent, secure purchase experience across merchants that choose to adopt an SRC solution. The reduced need for entering card and shipping information has the potential to lower shopping cart abandonment for merchants. SRC participants will also benefit from a simplified integration, thanks to the definition of consistent communications and interfaces across the digital commerce environment.

EMVCo outlines the following process for feedback submission and consideration by EMVCo:

  • All interested stakeholders are invited to submit feedback on EMV SRC Specification v0.9 within the 45 day public comment period, ending on Monday 3 December.
  • The draft EMV SRC Specification can be found on the EMVCo website .
  • Feedback submissions can be made via the public queries mechanism on the EMVCo website .
  • Feedback can be made privately or publicly via an option on the EMVCo website. EMVCo will review comments and publish its responses to public comments received. A plan will be established to incorporate applicable recommendations that will help facilitate global interoperability as the EMV SRC Specification evolves.

EMVCo encourages new participants who are interested in contributing to EMV initiatives to join the EMVCo Associates Programme or become an EMVCo Subscriber.

EMV® SRC Specification v1.0 will be published in 2019 and made available for royalty-free download from EMVCo’s website by all interested parties.

– ENDS –

Notes to Editors:

EMV® is a registered trademark in the U.S. and other countries and an unregistered trademark elsewhere. The EMV trademark is owned by EMVCo, LLC.

About EMVCo:

EMVCo is the global technical body that facilitates the worldwide interoperability and acceptance of secure payment transactions by managing and evolving the EMV Specifications and related testing processes. EMV is a technology toolbox that enables globally interoperable secure payments across face-to-face and remote environments. Adoption of EMV Specifications and associated approval and certification processes promotes a unified international payments framework, which supports an advancing range of payment methods, technologies and acceptance environments. The specifications are available royalty free, designed to be flexible, and can be adapted regionally to meet national payment requirements and accommodate local regulations.

EMVCo is collectively owned by American Express, Discover, JCB, Mastercard, UnionPay and Visa, and focuses on the technical advancement of the EMV Specifications. To provide all payment stakeholders with a platform to engage in its strategic and technical direction, EMVCo operates an Associates Programme and encourages all interested parties to get involved.

Visit www.emvco.com for further information and join EMVCo on LinkedIn .

Contact:

For EMVCo media Dave Amos, +44 113 3501922 david@iseepr.co.uk or Andrew Peacock, +44 113 3501922 andrew@iseepr.co.uk

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye